MicroPort CardioFlow Medtech Corporation provided group earnings guidance for the year ended December 31, 2022. For the period, the Group is expected to record a revenue of no less than RMB 250 million for the year ended December 31, 2022, representing an increase of approximately 25% as compared to that of the year ended December 31, 2021 and, net loss of approximately RMB 440 million to RMB 470 million for the year ended December 31, 2022, compared to approximately RMB 183 million for the year ended December 31, 2021.